Kvinner er kraftig underrepresentert både i ledelsen og i styrene til helsestartups. Ingrid Teigland Akay…
Continue Reading-
Galecto Publishes GB0139 Phase 2a (IPF) Results in European Respiratory Journal
Galecto Publishes GB0139 Phase 2a Idiopathic Pulmonary Fibrosis (IPF) Results in European Respiratory Journal, Showing…
Continue Reading -
Abliva receives positive regulatory feedback from UK MHRA on KL1333 Phase II/III study plan
Abliva AB (Nasdaq Stockholm: ABLI), a clinical-stage biopharmaceutical company developing medicines for the treatment of…
Continue Reading -
Abliva initiates a drug-drug interaction study and paves the way for a KL1333 pivotal study in 2021
Abliva AB (Nasdaq Stockholm: ABLI), a clinical-stage biopharmaceutical company developing medicines for the treatment of…
Continue Reading -
Oncoinvent Advances Radspherin® to Third Dose Level in Ongoing Phase 1 Clinical Trial
Safety review of second dose-level cohort allows study to advance to third cohort of colorectal…
Continue Reading -
Galecto Announces Pricing of Initial Public Offering
BOSTON and COPENHAGEN, Denmark, Oct. 28, 2020 (GLOBE NEWSWIRE) — Galecto, Inc. (NASDAQ: GLTO), a…
Continue Reading -
Neuro Event Labs Receives FDA Breakthrough Device Designation for Nelli®
SAN ANTONIO (PRWEB) OCTOBER 22, 2020 Neuro Event Labs, Inc., a global diagnostic company, announced that…
Continue Reading -
Abliva doses the first patient in its KL1333 Phase Ia/b clinical study
Abliva AB (Nasdaq Stockholm: ABLI) today announced that the first primary mitochondrial disease patient in…
Continue Reading -
GALECTO
Galecto is a Danish drug development company based in Copenhagen...
Continue Reading -
Hadean Ventures invest in Galecto`s $64 million round equity financing
Funds will support preparations for potential EU conditional approval of GB0139 in IPF and multiple…
Continue Reading